We and others have investigated the GalNAc-siRNA strategy as an antihypertensive approach in multiple preclinical hypertension rodent models (Table), including the spontaneously hypertensive rat (SHR), the 5/6th nephrectomy Sprague-Dawley (SD) rat,10 the deoxycorticosterone acetate (DOCA)-salt–treated SD rat, and the diabetic TGR(mRen2)27 rat.15 The latter rat overexpresses mouse renin and thus represents a model of Ang II–dependent hypertension. This evidence concerns the gene AGT and hypertensive disorder.